TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its...
BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to...
CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical...
EVEXIAS Health Solutions founder's first-of-its-kind book debunks the myths and misconceptions surrounding hormones in women and menSOUTHLAKE, TX / ACCESSWIRE...
Dana Dornsife, Founder and Chief Mission and Strategy Officer, Recognized by AACI for Advocating for Equity and Access Around Cancer...
Oral Health Pro with CancerDetect™ is the first-of-its-kind designed to provide essential oral health insights with the goal of hyper-personalized...
New customer orders received in Q3 exceed $1M annualized revenueNEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer...
NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced...
Continues SRT-100+™ customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla. , Sept....
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered...
Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS...
ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed...
Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential...
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company...
BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today...
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their...
Evidence from multiple researchers supports Vigil enhancement of clonal neoantigen effector cell response and correlation to relapse free survival and...
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to...
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a...